Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2020 Filed Sep 19, 2020 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 5,100 | $47.46 | $242,046.00 |
DisclosureSEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,580 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.18 to 48.14, inclusive. Read SEC document |
| September 16, 2020 Filed Sep 19, 2020 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 5,000 | $46.45 | $232,250.00 |
DisclosureSEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,738,680 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.11 to 47.07, inclusive. Read SEC document |
| September 16, 2020 Filed Sep 19, 2020 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 6,180 | $45.47 | $281,004.60 |
DisclosureSEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,788,680 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.08 to 46.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| September 16, 2020 Filed Sep 19, 2020 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 16,680 | $0.33 | $5,504.40 |
DisclosureSEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:00 UTC |
SANG CHARLESSVP, External Affairs
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · derivative · entry 6 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 25,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:00 UTC |
SANG CHARLESSVP, External Affairs
|
SaleCommon Stock | 25,000 | $44.00 | $1,100,000.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 4 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:00 UTC |
SANG CHARLESSVP, External Affairs
|
Exercise / conversionCommon Stock | 25,000 | $6.32 | $158,000.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 3 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 2,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-050779 · doc4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 2,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:00 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 2,000 | $42.58 | $85,160.00 |
DisclosureSEC source: 0001209191-20-050779 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionCommon Stock | 2,000 | $7.80 | $15,600.00 |
DisclosureSEC source: 0001209191-20-050779 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-20-050781 · doc4.xml · derivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 2,000 | $42.58 | $85,160.00 |
DisclosureSEC source: 0001209191-20-050781 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionCommon Stock | 2,000 | $0.45 | $900.00 |
DisclosureSEC source: 0001209191-20-050781 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:00 UTC |
SANG CHARLESSVP, External Affairs
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · derivative · entry 5 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:00 UTC |
SANG CHARLESSVP, External Affairs
|
SaleCommon Stock | 25,000 | $42.50 | $1,062,500.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 2 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.50 to 42.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 21:00 UTC |
SANG CHARLESSVP, External Affairs
|
Exercise / conversionCommon Stock | 25,000 | $6.55 | $163,750.00 |
DisclosureSEC source: 0001209191-20-050780 · doc4.xml · nonDerivative · entry 1 SANG CHARLES · CIK 0001780656 · SVP, External Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2020 Filed Sep 12, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 8,588 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-050224 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,000 Underlying: Common Stock · 8,588 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 11, 2020 Filed Sep 12, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 8,588 | $40.00 | $343,520.00 |
DisclosureSEC source: 0001209191-20-050224 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| September 11, 2020 Filed Sep 12, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 8,588 | $6.32 | $54,276.16 |
DisclosureSEC source: 0001209191-20-050224 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| September 11, 2020 Filed Sep 12, 2020 01:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,149 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-050225 · doc4.xml · derivative · entry 6 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 4,149 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 11, 2020 Filed Sep 12, 2020 01:00 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 4,149 | $40.00 | $165,960.00 |
DisclosureSEC source: 0001209191-20-050225 · doc4.xml · nonDerivative · entry 4 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| September 11, 2020 Filed Sep 12, 2020 01:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionCommon Stock | 4,149 | $7.80 | $32,362.20 |
DisclosureSEC source: 0001209191-20-050225 · doc4.xml · nonDerivative · entry 3 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 1,412 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-050224 · doc4.xml · derivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,588 Underlying: Common Stock · 1,412 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 1,412 | $40.00 | $56,480.00 |
DisclosureSEC source: 0001209191-20-050224 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 1,412 | $6.32 | $8,923.84 |
DisclosureSEC source: 0001209191-20-050224 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 18 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-050225 · doc4.xml · derivative · entry 5 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,149 Underlying: Common Stock · 18 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:00 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 18 | $40.00 | $720.00 |
DisclosureSEC source: 0001209191-20-050225 · doc4.xml · nonDerivative · entry 2 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| September 10, 2020 Filed Sep 12, 2020 01:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionCommon Stock | 18 | $7.80 | $140.40 |
DisclosureSEC source: 0001209191-20-050225 · doc4.xml · nonDerivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 20,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-049873 · doc4.xml · derivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,000 Underlying: Common Stock · 20,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 23:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 20,000 | $36.17 | $723,400.00 |
DisclosureSEC source: 0001209191-20-049873 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 23:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 20,000 | $6.32 | $126,400.00 |
DisclosureSEC source: 0001209191-20-049873 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 23:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,083 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-049872 · doc4.xml · derivative · entry 3 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,167 Underlying: Common Stock · 2,083 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 23:00 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 2,083 | $36.17 | $75,342.11 |
DisclosureSEC source: 0001209191-20-049872 · doc4.xml · nonDerivative · entry 2 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 23:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionCommon Stock | 2,083 | $7.80 | $16,247.40 |
DisclosureSEC source: 0001209191-20-049872 · doc4.xml · nonDerivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock (Right to Buy) · Derivative | 1,563 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · derivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 1,563 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · derivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,105 Underlying: Common Stock · 2,604 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · derivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,459 Underlying: Common Stock · 2,604 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 300 | $41.75 | $12,525.00 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 6,471 | $41.28 | $267,122.88 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.72 to 41.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 1,563 | $7.27 | $11,363.01 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-20-049271 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-048165 · doc4.xml · derivative · entry 7 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,646 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,109 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-048165 · doc4.xml · derivative · entry 6 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,254 Underlying: Common Stock · 1,109 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 220 | $43.36 | $9,539.20 |
DisclosureSEC source: 0001209191-20-048165 · doc4.xml · nonDerivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.31 to 43.80, inclusive. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 1,400 | $42.92 | $60,088.00 |
DisclosureSEC source: 0001209191-20-048165 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,520 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.46 to 43.23, inclusive. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 1,260 | $42.07 | $53,008.20 |
DisclosureSEC source: 0001209191-20-048165 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,920 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.50 to 42.33, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-20-048165 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,109 | $7.80 | $8,650.20 |
DisclosureSEC source: 0001209191-20-048165 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-048166 · doc4.xml · derivative · entry 12 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,600 Underlying: Common Stock · 11,100 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.